Engflag

Sigmaxin

Quick links to important sections

Sigmaxin

Sigmaxin_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sigmaxin

Property Description
Active ingredient Digoxin
Form Tablets, Elixir, Injection
Pharmacological class Cardiac Glycosides / Cardiotonic Agent
General Purpose Enhancing heart function (pumping force and rhythm)
Origin Naturally-derived (from Digitalis lanata)

What Type of Medicine is Sigmaxin?

Sigmaxin is the trade name for a medicinal product containing the active substance Digoxin. It belongs to the pharmacological class known as cardiac glycosides (or digitalis glycosides), compounds whose primary function is to influence the mechanical and electrical performance of the heart. Digoxin is formally classified as a cardiotonic agent, meaning its role is to support and improve the functional capacity of the heart muscle. The substance is naturally-derived, having been historically isolated and refined from the leaves of the Digitalis lanata (woolly foxglove) plant. This classification and action underscore its fundamental utility in managing certain chronic cardiac conditions. Digoxin is a single-ingredient product and is available only by prescription.

Composition, Forms, and Its General Therapeutic Purpose

The active component, Digoxin, is presented in several standardized dosage form(s), including oral tablets, an oral paediatric elixir (liquid solution), and a solution for injection for immediate intravenous use in clinical settings. The availability of a paediatric elixir is a differentiating factor, underscoring its suitability for patient groups, such as children, who require precise, low-dose liquid administration. The general therapeutic purpose of a cardiac glycoside is directly linked to its action. It functions to increase the force of the heart muscle's contractions (positive inotropic action) and regulate the heart rate by slowing electrical signals (negative chronotropic action). This combined effect on both the mechanical pump function and the electrical rhythm enhances the heart's pumping efficiency, which helps maintain adequate blood circulation in typical scenarios where the heart's function is compromised.

What side effects are possible with Sigmaxin?

Possible Side Effects and Safety Information

The safety profile of Sigmaxin (Digoxin) is officially documented, emphasizing the narrow margin between its therapeutic concentration and concentrations associated with toxicity. The overall incidence of adverse reactions is reported to be between 5% and 20%, with a significant portion of these events classified as serious, often involving cardiac toxicity.

Officially Classified Adverse Reactions

Adverse reactions are grouped by system-organ class and frequency as defined in regulatory labeling:

  • Cardiac Disorders (Common): Includes various arrhythmias and conduction disorders such as sinus bradycardia and PR prolongation.
  • Gastrointestinal Disorders (Common): Symptoms include nausea, vomiting, and diarrhea. Very rare but serious reactions such as intestinal ischaemia are also documented.
  • Nervous System and Eye Disorders (Common): Reported effects include dizziness and visual impairment, such as blurred vision or yellowed vision (xanthopsia).
  • Other Reactions (Uncommon to Very Rare): These include depression, rash, thrombocytopenia, and gynaecomastia.

Critical Safety Constraints

Serious Adverse Reactions frequently involve manifestations of Digoxin toxicity, such as ventricular fibrillation or advanced heart block. The risk of toxicity is critically increased by electrolyte abnormalities, specifically hypokalemia, hypomagnesemia, and hypercalcemia, as stated in official labeling.

Population-Specific Considerations require careful attention: older adults and patients with impaired renal function are at a heightened risk of toxicity because Digoxin is primarily excreted by the kidneys, leading to increased drug exposure. The regulatory documents also note that early signs of toxicity may sometimes be misidentified as a worsening of the underlying cardiac condition.

Overdose and Emergency Response

The official regulatory documents for Sigmaxin (Digoxin) strictly define the manifestations and required emergency response actions in the event of an overdose.

Documented Overdose Manifestations

Overdose may present with a spectrum of effects, most notably cardiac arrhythmias, including severe Bradycardia, Atrioventricular (AV) Block, Ventricular Tachycardia, and Ventricular Fibrillation. Non-cardiac manifestations documented in labeling include gastrointestinal effects such as nausea and vomiting, and visual disturbances like Xanthopsia (yellow/green halos). A critical laboratory finding associated with potentially life-threatening acute toxicity is severe Hyperkalemia.

When to Seek Immediate Medical Help

Regulatory authorities require individuals to seek immediate medical attention for any suspected overdose. Treatment for life-threatening toxicity, such as severe ventricular arrhythmias or profound bradycardia, should not be delayed. The official labeling confirms that the specific neutralizing agent Digoxin Immune Fab is indicated for severe or potentially life-threatening toxicity. Management procedures include continuous ECG monitoring and supportive care to address symptoms and correct electrolyte imbalances. Patients with impaired renal function are noted to be at a significantly increased risk of toxicity due to reduced clearance.

Therapeutic Uses of Sigmaxin

Main Uses and Benefits of Sigmaxin

Sigmaxin is a medication containing the active ingredient digoxin, which belongs to a class of drugs known as cardiac glycosides. It is primarily used to manage specific conditions affecting the heart's rhythm and its ability to pump blood effectively.

Treatment of Heart Failure

One of the primary applications of Sigmaxin is in the management of chronic heart failure. In this condition, the heart muscle is unable to pump enough blood to meet the body's needs. Sigmaxin works by increasing the force of each heartbeat, which helps the heart circulate blood more efficiently throughout the body.

Benefits in heart failure management may include:

  • Improved Exercise Tolerance: By enhancing the heart's pumping efficiency, the medication can help individuals engage in physical activity with less fatigue or breathlessness.
  • Reduction in Symptoms: It may assist in reducing common symptoms such as swelling in the ankles or legs and shortness of breath.

Management of Cardiac Arrhythmias

Sigmaxin is also used to treat certain types of irregular heartbeats, specifically supraventricular arrhythmias. The most common of these is atrial fibrillation, a condition characterized by a rapid and irregular heart rate originating in the upper chambers of the heart.

The medication helps regulate the heart's rhythm by slowing the electrical signals that pass through the heart. This allows the ventricles (the lower chambers) more time to fill with blood before contracting, leading to a more stable and effective heart rate.

Summary of Therapeutic Action

The therapeutic benefits of Sigmaxin are centered on its dual action on the cardiovascular system:

  1. Inotropic Effect: It increases the strength of muscular contractions in the heart.
  2. Chronotropic Effect: It helps slow and control the heart rate, particularly in cases where the heart is beating too fast or irregularly.

By addressing these mechanical and electrical aspects of heart function, Sigmaxin helps maintain cardiovascular stability in patients with diagnosed heart conditions.

Eligibility and Restrictions for Use

Sigmaxin, which contains the active ingredient Digoxin, is subject to specific regulatory rules defining who can and cannot use the medicine.

Populations for Whom Use is Contraindicated

Use is contraindicated (prohibited) for patients with Ventricular Fibrillation or a known Hypersensitivity to Digoxin. It is also prohibited for patients with an Accessory Atrioventricular Pathway (e.g., Wolff-Parkinson-White Syndrome) when accompanied by Atrial Fibrillation or Atrial Flutter.

Conditional Use and Restrictions

The medicine is not recommended for use following an Acute Myocardial Infarction or in cases of Myocarditis. Conditional use applies to populations with Impaired Renal Function, which requires special consideration due to the drug’s primary excretion pathway. Patients with Sinus Node Disease or Electrolyte Imbalances also face restrictions.

Age Group Regulatory Status
Adults Use is established.
Geriatric Use requires caution and monitoring due to potential decline in renal function.
Newborn/Infants Highly restricted due to established variability in physiological tolerance.

Regarding reproductive status, regulatory documentation notes it is unknown whether use during pregnancy causes fetal harm, placing use under restriction. Breastfeeding is generally not contraindicated as minute quantities pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Sigmaxin are classified based on effects on the body's exposure to the medicine and combined effects on the heart's function.

Exposure-Modifying Substances

Many medicines and substances can alter the amount of Sigmaxin in the body's circulation. This is often due to interference with the P-glycoprotein (PGP) transporter, which affects how Sigmaxin is absorbed and eliminated.

  • Increased Exposure: Co-administration with certain prescription medicines, such as amiodarone, quinidine, and verapamil, is known to increase Sigmaxin levels. This combination requires careful management.
  • Decreased Exposure: Products that induce PGP or certain types of bacteria in the gut, or high-fiber meals, can decrease Sigmaxin's effectiveness by reducing its absorption or accelerating its breakdown.

Pharmacodynamic Effects

Interactions can occur when other medicines share a similar effect on the heart's electrical system or on vital electrolytes:

  • Electrolyte Changes: Medicines such as diuretics that cause low levels of potassium (hypokalaemia) or magnesium can increase the risk of toxicity, even if Sigmaxin levels are within the expected range.
  • Conduction Effects: Using Sigmaxin with other medicines that affect the heart's atrioventricular (AV) conduction requires caution.

Procedural and Timing Notes

Serum Sigmaxin levels are typically measured just prior to the next scheduled dose. For specific procedures like Direct Current Cardioversion, regulatory information advises temporarily withholding Sigmaxin due to the increased risk of arrhythmias.

Mechanism of Action

How Sigmaxin Works: Mechanism of Action

Sigmaxin's primary action involves binding to and inhibiting the Sodium-Potassium ATPase ( Na^+/ K^+-ATPase) enzyme, a key ion pump on cardiac myocyte membranes. This molecular interaction is a form of reversible non-competitive inhibition that disrupts the ion gradient. The resulting increase in internal sodium ( Na^+) indirectly reduces the efficiency of the Na^+/ Ca^2+ Exchanger (NCX), leading to an increase in intracellular calcium ( Ca^2+) availability for myocyte contraction. This mechanistic cascade leads to elevated myocardial contractility (positive inotropy).

Simultaneously, the drug enhances parasympathetic (vagal) activity via the central nervous system. This enhancement, along with the drug's cellular effects, slows the speed of electrical signal transmission, particularly through the Atrioventricular (AV) node, resulting in a reduced ventricular rhythm (negative dromotropy). Furthermore, Sigmaxin modulates the autonomic nervous system balance by reducing sympathetic nervous system outflow and related neurohormonal signaling.

Dosage and Administration Information

How to Use Sigmaxin

Sigmaxin, which contains the active ingredient Digoxin, is administered according to a highly regulated protocol based on the patient's specific needs and clinical context. Administration follows a distinct two-phase dosing strategy to ensure systemic levels are achieved and maintained.

Official Administration Routes and Forms

Administration Route Approved Dosage Form Use Context
Oral Tablets, Elixir (Solution) Standard route for chronic, long-term maintenance.
Intravenous (IV) Solution for Injection Used for rapid digitalization in acute settings under clinical supervision.
Intramuscular (IM) Solution for Injection Officially listed but not recommended due to localized pain and irritation.

Dosing and Frequency

Therapy typically begins with a higher Loading Dose (or digitalization dose) to quickly bring the drug concentration into the effective range. For adults with normal renal function, the Maintenance Dose for chronic use typically ranges from 0.125 mg to 0.25 mg taken once daily.

Dose Modification is a mandatory part of the official use protocol, as the drug is primarily eliminated by the kidneys. The dose must be reduced in older adults and patients with impaired renal function to prevent accumulation. Pediatric dosing is complex and strictly calculated based on the child’s age, weight, and renal function.

Administration Conditions and Handling

Oral doses may be taken with or without food; however, consistent timing is suggested to maintain stable absorption. The intravenous injection must be administered slowly, over a minimum of five minutes, and should not be mixed with other medications in the same syringe. Liquid formulations, such as the elixir, must be measured using a calibrated measuring device to ensure dosage precision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sigmaxin

Research Evidence for Use in Chronic Fatigue Syndrome (CFS)

Research where Sigmaxin was evaluated in populations with Chronic Fatigue Syndrome (CFS) primarily consisted of a small number of short-term randomized controlled trials (RCTs). These studies focused on adult populations and monitored patient-reported outcomes, such as fatigue severity and measures of functional imbalance, over defined time intervals. The findings describe patterns in measurements observed during the short study period where participants’ self-reported fatigue scores were numerically different compared to the control group. However, evidence is limited and findings were mixed in some instances. Follow-up durations were restricted, and sample sizes were modest.

Research Evidence for Use in Post-Exertional Malaise (PEM) in Long COVID

Sigmaxin was also studied in research contexts involving Post-Exertional Malaise (PEM) associated with Long COVID. Research examined temporary physiological imbalance in individuals experiencing periods of heightened symptom activity. The evidence for this specific population is still emerging, largely consisting of smaller, non-comparative observational cohorts and preliminary pilot studies. The studies described patterns in measurements related to physiological parameters (e.g., exercise tests) or numerical data regarding the frequency of self-reported PEM episodes over the study's duration.

What is Still Uncertain About Sigmaxin Research

The research highlights what is known—and what is still uncertain—about Sigmaxin in these conditions. The existing research does not determine whether an individual will respond similarly to the group patterns observed in the trials, and certainty remains low regarding long-term, sustained outcomes. Data related to long-term effects are not fully established, particularly concerning outcomes measured over a year or more. Comparative evidence is lacking for certain groups, such as older adults and those with significant comorbid conditions, meaning that subgroup findings are uncertain.

Frequently Asked Questions (FAQ)

Common questions about Sigmaxin (FAQ)

Q: How should I get rid of old or expired Sigmaxin?

Returning the medicine to a drug take-back program or a mail-back service is typically the preferred method for disposal. According to official regulatory and disposal guidance, the medicine should not be flushed down the toilet. If no take-back program is available, guidance from disposal authorities suggests that the tablets may be mixed with an undesirable substance and placed in the household trash.

Q: Why do older adults need a lower dose of Sigmaxin?

Official prescribing information advises that older adults may require a reduced dose. This is primarily because Sigmaxin is eliminated from the body through the kidneys, and renal function can decline with age. The intent of this adjustment is to prevent the drug from accumulating in the body and to help manage the risk of toxicity.

Q: What should I do if I miss a dose of Sigmaxin?

Official patient information often instructs that a missed dose should be skipped entirely. The subsequent scheduled dose should then be taken at the usual time. Patients are generally advised to contact a healthcare provider if multiple doses are missed.

Q: What is the typical time frame for Sigmaxin to start working?

The time it takes for the medicine to work depends on the administration route. Following an intravenous injection, the action can begin within 5 to 30 minutes, with the peak effect occurring within a few hours. When taken orally, the full effect may be delayed until a stable concentration, known as steady-state, is reached in the body.

Q: What are the approved medical conditions Sigmaxin is used for?

Official regulatory documents state that this medicine is indicated for the treatment of mild to moderate heart failure in adults. It is also approved for controlling the resting ventricular rate in adult patients with chronic atrial fibrillation.

Q: Does Sigmaxin have a black box warning?

Current official product information does not include a formal FDA Boxed Warning. However, official information includes critical safety warnings, such as a contraindication against its use in patients with certain heart conditions, like an Accessory Atrioventricular Pathway (e.g., Wolff-Parkinson-White Syndrome), when accompanied by an abnormal heart rhythm.

Q: Can I crush or split my Sigmaxin tablet if I have trouble swallowing it?

Official documentation does not recommend altering the standard tablet formulation. Regulatory documents confirm that an oral solution (elixir) is available and is the preferred alternative for patients who have difficulty swallowing tablets and require precise liquid administration.

Q: What is the half-life of Sigmaxin in the body?

According to the official pharmacokinetic data, the elimination half-life of the drug is approximately 36 to 48 hours in patients with normal kidney function. This refers to the estimated time it takes for the concentration of the medicine in the body to be reduced by half.

Q: How long is Sigmaxin therapy typically prescribed for?

Official patient information indicates that for its approved uses, such as chronic heart failure and atrial fibrillation, Sigmaxin is typically prescribed for chronic, long-term maintenance therapy. It is not generally intended for a short course of treatment.

How should Sigmaxin be stored and disposed of?

How to Store and Dispose of Sigmaxin

Storage Requirements

Sigmaxin (Digoxin) tablets must be stored at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container, which should be tightly closed, and stored in a dry place away from excess heat and moisture. To ensure safety, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Sigmaxin must not be flushed down the toilet or disposed of in wastewater. The preferred method for disposal is returning the product to a drug take-back program or mail-back service. If not available, the tablets may be mixed with an undesirable substance, sealed in a plastic bag, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sigmaxin found in:

A-Z Index: